\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
New York, NY and Tel Aviv, ISRAEL, August 31, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and similar response company, announced today which has entered into a lease on the Cleburn, Texas domain for 15,200 square feet on 6 acres, with botanical extraction, distillation, and finished product production capabilities. The facility is capable of generating Tollovid™, the 3CL protease inhibitor immune nutritional supplement from 3CL Pharma’s majority-owned subsidiary, 3CL Pharma’s Ltd. , as well as other immune supplement ingredients that would potentially be added to new Tollovid formulations , adding vitamin C and CBD. -A. The facility currently has more than $2,000,000 worth of botanical production apparatus for the production of supplements and medicines. You can make products from various embodiments of botanical extracts, adding capsules, tinctures, gummies, beverages, and syrups. The land on which the facility is located, as well as its access to the water supply, gives Everyone the opportunity to identify growing possibilities for years to come and has enough domain to eventually produce up to 30,000,000 bottles of Tollovid per month. The facility has all the popular ongoing compliance procedures (SOPs) required to achieve existing smart manufacturing practices (cGMP), and the company expects the facility to achieve cGMP status by the end of the year. year 2022.
“We have spent the last two years incubating Tollovid with a focus on building insights into its in vitro 3CL protease activity and its effects in clients with acute and long-standing infections,” said Gerald E. CommissiongArray, President and CEO of Todos Medical. . “We have had several conversations with foreign suppliers who value the “Made in USA” quality of the Tollovid logo and the knowledge that we have generated to date. Through this production initiative, we are able to bring our COGS to a point where we can be competitive in the foreign supplement market. This allows us to have complete control over the production process, which means that we are now in a much more wonderful position to scale. Over the past month, as we finalized plans around this initiative, the team we recruited to run the lab that worked in conjunction with a former CBD manufacturer for over five years was able to protect our first two users. White label CBD that delivered the red tape of the initial order for the isolate capsules. We, those first two consumers, will enable the new contract production business unit to be cash flow positive without delay and give us confidence that we can moderately grow this business without significant investment of working capital while we prepare to expand marketing and distribution for Tollovid. at national and foreign level. Texas is a wonderful state to do business in and we are excited about the relationships we plan to build through this strategically located facility.
About Todos Medical Ltd. Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs important diagnostic responses for the early detection of various types of cancer. The company’s proprietary infrared biochemical analyses (TBIs) are a proprietary cancer detection generation that employs peripheral blood research that examines the influence of cancer on the immune system, looking for biochemical adjustments in blood mononuclear cells and plasma. The two cancer screening tests evolved internally through All, TMB-1 and TMB-2, have earned ce marking in Europe. All recently acquired the U. S. -founded medical diagnostics company. USA Provided Diagnostics, Inc. to offload the rights to its qualified CLIA/CAP laboratory founded in Alpharetta, Georgia, which is recently conducting COVID PCR, Long COVID Panel and Videssa® breast cancer testing on Provista’s proprietary advertising-level blood test. You can learn more about Provided at www. provistadx. com.
All are also performing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. Lymphocyte Proliferation Control (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to be exogenous mitogens. stimulation that activates them to enter the mobile cycle. Some diseases, including Alzheimer’s disease, are thought to be the result of compromised mobile machinery leading to aberrant re-entry of the mobile cycle through neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a replacement for neuronal mobile function, suggesting a non-unusual dating between PBLs and neurons in the brain.
All formed the majority-owned joint venture based in Israel 3CL Pharma, Ltd. with NLC Pharma in March 2022 to consolidate all intellectual assets around 3CL protease-based diagnostic tests and the progression of botanical and pharmaceutical 3CL protease inhibitors that target a basic reproductive system. . 3CL Pharma, through the Todos brand, has announced the protease inhibitor 3CL Tollovid™, an immune-supporting nutritional supplement, in the United States, is introducing the dual-mechanism 3CL protease inhibitor and the anti-cytokine curative drug candidate Tollovir™, while also soon the 3CL Protease Diagnostic TolloTest™. To purchase Tollovid, visit Amazon or www. MyTollovid. com. For more information, see https://www. todosmedical. com/.
Certain statements contained in this press release may possibly constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical trials and clinical progression systems. These forward-looking statements are based solely on existing control expectations and are subject to vital dangers and uncertainties that may also cause actual effects to differ materially from those described in the forward-looking statements, adding dangers and uncertainties related to the ProgressArray timing, burden and effects of clinical trials and product progression systems; difficulties or delays in discharging regulatory approval or patent coverage for candidate products; festival of other biogeneration companies; and our ability to offload the additional funding necessary to carry out our research, development and commercialization activities. In addition, the following factors, among others, may also cause actual effects to differ materially from those described in the forward-looking statements: adjustments to generation and market requirements; delays or obstacles in starting our clinical trials; adjustments in the legislation; failure to expand and introduce new technologies, products and programs in a timely manner; lack of validation of our generation as we move forward and lack of acceptance of our strategies throughout the clinical community; inability to retain or attract key workers whose wisdom is essential to the progression of our products; unforeseen clinical difficulties that could possibly expand with our process; final product load higher than expected; loss of market share percentage and pressure on charges resulting from the festival; and laboratory effects that do not translate to similar intelligent effects under actual conditions, which may also cause actual effects or functionality to differ materially from those implied by such forward-looking statements. Except as otherwise required by law, Todos Medical assumes no legal responsibility to publish any revisions to such forward-looking statements to reflect events or events after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the dangers and uncertainties affecting Todos Medical, please refer to its reports filed periodically with the United States Securities and Exchange Commission.
All Corporate Contact 😀 HirschCFOTodos Medical917-983-4229 x 104Dan. h@todosmedical. com
All Press Contact:Kyle KappmeierJConnellyVicepresidente973-975-7827kkapmeier@jconnelly. com